Unknown

Dataset Information

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer.


ABSTRACT: Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor. Since olaparib is a newly approved drug, there are few reports of skin disorders that may be triggered by olaparib administration. In this report, we present a case with an olaparib-induced drug eruption presenting multiple purpuras on the patient's fingers and fingertips. The present case suggests that olaparib might induce purpura as nonallergic drug eruption.

SUBMITTER: Sekine M 

PROVIDER: S-EPMC10294207 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature